<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="54419">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02397694</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-141-1475</org_study_id>
    <nct_id>NCT02397694</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety and tolerability of bictegravir (BIC) +
      emtricitabine/tenofovir alafenamide (FTC/TAF) fixed dose combination (FDC) versus
      dolutegravir (DTG) + FTC/TAF in HIV-1 Infected, antiretroviral treatment-naive adults. This
      study will also evaluate the pharmacokinetic (PK) profile of BIC, FTC and TAF.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt; 50 copies/mL as determined by the FDA-defined snapshot algorithm.</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt; 50 copies/mL as determined by the FDA-defined snapshot algorithm.</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt; 50 copies/mL as determined by the FDA-defined snapshot algorithm.</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in log10 HIV-1 RNA and in CD4+ cell count</measure>
    <time_frame>Weeks 12, 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of treatment-emergent adverse events (AEs) and treatment-emergent laboratory abnormalities.</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BIC, FTC, and TAF</measure>
    <time_frame>Week 4 or 8</time_frame>
    <description>For a subset of participants who enroll in the PK substudy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed plasma concentration (Tmax) of BIC, FTC, and TAF</measure>
    <time_frame>Week 4 or 8</time_frame>
    <description>For a subset of participants who enroll in the PK substudy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed drug concentration at the end of the dosing interval (Ctau) for BIC, FTC, and TAF</measure>
    <time_frame>Week 4 or 8</time_frame>
    <description>For a subset of participants who enroll in the PK substudy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve over the dosing interval (AUCtau) for BIC, FTC, and TAF</measure>
    <time_frame>Week 4 or 8</time_frame>
    <description>For a subset of participants who enroll in the PK substudy. AUCtau is defined as concentration of drug over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate of the terminal elimination half-life (t1/2) of BIC, FTC, and TAF</measure>
    <time_frame>Week 4 or 8</time_frame>
    <description>For a subset of participants who enroll in the PK substudy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentrations for BIC, FTC, and TAF</measure>
    <time_frame>Weeks 4, 8, 12 and 24</time_frame>
    <description>This endpoint will measure the plasma concentrations of BIC, FTC, and TAF.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>BIC + FTC/TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive BIC + FTC/TAF FDC + DTG placebo for 48 weeks.
Following Week 48, participants will continue to take their blinded treatment and attend visits every 12 weeks until treatment assignments have been unblinded. Participants will return for an unblinding visit and be given the option to participate in an open-label rollover extension and receive bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) until it becomes commercially available, or until Gilead Sciences elects to terminate the development of BIC/F/TAF.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DTG + FTC/TAF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive DTG + FTC/TAF FDC + BIC placebo for 48 weeks.
Following Week 48, participants will continue to take their blinded treatment and attend visits every 12 weeks until treatment assignments have been unblinded. Participants will return for an unblinding visit and be given the option to participate in an open-label rollover extension and receive BIC/F/TAF until it becomes commercially available, or until Gilead Sciences elects to terminate the development of BIC/F/TAF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIC</intervention_name>
    <description>75 mg tablet administered orally once daily</description>
    <arm_group_label>BIC + FTC/TAF</arm_group_label>
    <other_name>GS-9883</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTC/TAF</intervention_name>
    <description>200/25 mg FDC tablet administered orally once daily</description>
    <arm_group_label>BIC + FTC/TAF</arm_group_label>
    <arm_group_label>DTG + FTC/TAF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTG</intervention_name>
    <description>50 mg tablet administered orally once daily</description>
    <arm_group_label>DTG + FTC/TAF</arm_group_label>
    <other_name>Tivicay®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIC Placebo</intervention_name>
    <description>Tablet administered orally once daily</description>
    <arm_group_label>DTG + FTC/TAF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTG Placebo</intervention_name>
    <description>Tablet administered orally once daily</description>
    <arm_group_label>BIC + FTC/TAF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIC/F/TAF</intervention_name>
    <description>50/200/25 mg FDC tablet administered orally once daily</description>
    <arm_group_label>BIC + FTC/TAF</arm_group_label>
    <arm_group_label>DTG + FTC/TAF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Antiretroviral naive (≤ 10 days of prior therapy with any antiretroviral agent)

          -  Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening

          -  Screening genotype report provided by Gilead Sciences must show sensitivity to
             tenofovir (TFV) and FTC

          -  Adequate renal function as measured by estimated glomerular filtration rate ≥ 70
             mL/min according to the Cockcroft-Gault formula

          -  CD4+ cell count &gt; 200 cells/µL at screening

        Key Exclusion Criteria:

          -  A new AIDS-defining condition diagnosed within the 30 days prior to screening as
             defined in the study protocol

          -  Prior use of antiretrovirals in the setting of pre-exposure prophylaxis (PrEP) or
             post exposure prophylaxis (PEP)

          -  Chronic hepatitis B virus (HBV) infection

          -  Hepatitis C infection (Individuals who are hepatitis C virus (HCV) Ab positive, but
             have a documented negative HCV RNA, are eligible)

          -  Active, serious infections (other than HIV-1 infection) requiring parenteral
             antibiotic or antifungal therapy within 30 days prior to baseline

          -  Participation in any other clinical trial without prior approval from the sponsor is
             prohibited while participating in this trial

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <zip>48072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 20, 2016</lastchanged_date>
  <firstreceived_date>March 20, 2015</firstreceived_date>
  <firstreceived_results_disposition_date>August 22, 2016</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult</keyword>
  <keyword>HIV</keyword>
  <keyword>naive</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
